ACRV vs ACXP

Acrivon Therapeutics, Inc. vs Acurx Pharmaceuticals, Inc. — Valuation Comparison 2026

ACRV

Biotechnology
Acrivon Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
24
SAFE
Price
$1.63
Last close
Models
7/13
Active
VS

ACXP

Biotechnology
Acurx Pharmaceuticals, Inc.
Quality
3.8
out of 10
Value Trap
18
SAFE
Price
$1.99
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ACRV Fair ValueACRV Upside ACXP Fair ValueACXP Upside
Bayesian DCF Intrinsic $0.85 -47.9% $1.71 -14.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.93 -43.2% $0.12 -94.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ACRV vs ACXP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ACRV vs ACXP — Which Stock Is More Undervalued?

ACRV scores higher with a 4.2/10 quality rating vs ACXP's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Acrivon Therapeutics, Inc. (ACRV) and Acurx Pharmaceuticals, Inc. (ACXP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ACRV currently trades at $1.63 with a QOC of 4.2/10, while ACXP trades at $1.99 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).